Phase II Trial of Metronomic Eribulin (Halaven) In Pretreated Metastatic Breast Cancer (MBC)

Trial Profile

Phase II Trial of Metronomic Eribulin (Halaven) In Pretreated Metastatic Breast Cancer (MBC)

Recruiting
Phase of Trial: Phase II

Latest Information Update: 27 Oct 2017

At a glance

  • Drugs Eribulin (Primary)
  • Indications Advanced breast cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 23 Oct 2017 Planned primary completion date changed from 1 Feb 2018 to 1 Aug 2018.
    • 11 Dec 2014 Trial design presented at the 37th Annual San Antonio Breast Cancer Symposium
    • 11 Dec 2014 According to a trial design presented at the 37th Annual San Antonio Breast Cancer Symposium, 12 patients have been enrolled to date
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top